| 2,615 | 82 | 227 |
| 下载次数 | 被引频次 | 阅读次数 |
肺癌目前仍是死亡率较高的恶性肿瘤。近年来随着分子靶向治疗的进展,非小细胞肺癌的治疗已经取得了长足的进步。许多转化性临床研究结果带来近期疗效、生活质量尤其是生存的显著提高。传统的化疗是非小细胞肺癌治疗的基石,是野生型以及突变未知患者治疗的首选;分子靶向治疗则为敏感突变的患者带来了革命性的转变,是目前治疗的中流砥柱;而免疫治疗在免疫检查点抑制剂上的突破也结束了长期混沌的状态,成为非小细胞肺癌治疗的新兴力量。而无论是化疗、靶向治疗还是免疫治疗,基于肿瘤分子病理改变的精确治疗是目前非小细胞肺癌治疗发展的趋势。
Abstract：Lung cancer is the leading cause of cancer mortality. Due to the progress in molecular target therapy, great progress has been achieved in advanced non-small cell lung cancer(NSCLC). Many treatments have been demonstrated to improve the objective remission rate, quality of life and even the progressive free survival and overall survival in translational researches. Traditional chemotherapy is very important for NSCLC patients, especially for those wild-type or unknown gene mutation patients; the progress in molecular target therapy just revolutionize the treatment of NSCLC and become the first choice for those patients with gene sensitive mutation; the progresses of drugs which target specific checkpoint of immune system have led the immunotherapy to new heights, immunotherapy become the new choice for NSCLC. No matter chemotherapy, target therapy or immunotherapy, the treatments based on exact change of the molecular pathogenesis are the development direction of NSCLC.
[1]Lynch TJ,Bell DW,Sordella R,et al.Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefi tinib[J].N Engl J Med,2004,350(21):2129-2139.
[2]Melosky B.Treatment algorithms for patients with metastatic nonsmall cell,non-squamous lung cancer[J].Front Oncol,2014,4:256.
[3]Ye T,Pan Y,Wang R,et al.Analysis of the molecular and clinicopathologic features of surgically resected lung adenocarcinoma in patients under 40 years old[J].J Thorac Dis,2014,6(10):1396-1402.
[4]Schiller JH,Harrington D,Belani CP,et al.Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer[J].N Engl J Med,2002,346(2):92-98.
[5]Jiang J,Liang X,Zhou X,et al.Non-platinum doublets were as effective as platinum-based doublets for chemotherapy-naive advanced non-small-cell lung cancer in the era of third-generation agents[J].J Cancer Res Clin Oncol,2013,139(1):25-38.
[6]尹月,邱新野,刘泽源.老年非小细胞肺癌患者化疗药物治疗进展[J].中国药物应用与监测,2012,9(3):169-172.
[7]Scagliotti GV,Parikh P,von Pawel J,et al.PhaseⅢstudy comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer[J].J Clin Oncol,2008,26(21):3543-3551.
[8]Cobo M,Isla D,Massuti B,et al.Customizing cisplatin based on quantitative excision repair cross-complementing 1 m RNA expression:a phaseⅢtrial in non-small-cell lung cancer[J].J Clin Oncol,2007,25(19):2747-2754.
[9]Bepler G,Williams C,Schell MJ,et al.Randomized international p hase Ⅲ trial of ERCC 1 and RRM 1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced nonsmall-cell lung cancer[J].J Clin Oncol,2013,31(19):2404-2412.
[10]Lynch TJ Jr,Spigel DR,Brahmer J,et al.Safety and effectiveness of bevacizumab-containing treatment for non-small-cell lung cancer:fi nal results of the ARIES observational cohort study[J].J Thorac Oncol,2014,9(9):1332-1339.
[11]Wu YL,Lee JS,Thongprasert S,et al.Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer(FASTACT-2):a randomised,doubleblind trial[J].Lancet Oncol,2013,14(8):777-786.
[12]Mok TS,Wu YL,Thongprasert S,et al.Gefi tinib or carboplatinpaclitaxel in pulmonary adenocarcinoma[J].N Engl J Med,2009,361(10):947-957.
[13]Kuiper JL1,Smit EF.Challenges in the management of EGFRmutated non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors[J].Oncology,2014,87(2):83-94.
[14]Peters S,Zimmermann S,Adjei AA.Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer:comparative pharmacokinetics and drug-drug interactions[J].Cancer Treat Rev,2014,40(8):917-926.
[15]Awad MM,Shaw AT.ALK inhibitors in non-small cell lung cancer:crizotinib and beyond[J].Clin Adv Hematol Oncol,2014,12(7):429-439.
[16]Audigier-Valette C,Girard N,Cortot AB,et al.ALK-rearranged non-small cell lung cancer:how to optimize treatment with crizotinib in routine practice?[J].Bull Cancer,2014,101(9):823-831.
[17]Shaw AT,Kim DW,Mehra R,et al.Ceritinib in ALK-rearranged non-small-cell lung cancer[J].N Engl J Med,2014,370(13):1189-1197.
[18]Gadgeel SM,Gandhi L,Riely GJ,et al.Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer(AF-002JG):results from the dose-finding portion of a phase 1/2 study[J].Lancet Oncol,2014,15(10):1119-1128.
[19]Zhang N,Yang JJ,Zhang XC,et al.Responses to crizotinib in a patient with c-ros oncogene 1,receptor tyrosine kinase-positive advanced lung adenocarcinoma:a case report[J].Oncol Lett,2014,8(6):2624-2626.
[20]Brustugun OT,Khattak AM,TrΦmborg AK.BRAF-mutations in non-small cell lung cancer[J].Lung Cancer,2014,84(1):36-38.
[21]王汉萍,张力.非小细胞肺癌免疫治疗的最新进展[J].癌症进展,2014,12(3):250-255.
[22]Wang S,Zhang H,Liu C,et al.Human leukocyte antigenhaploidentical donor-derived cytokine-induced killer cells are safe and prolong the survival of patients with advanced non-small cell lung cancer[J].Oncol Lett,2014,8(6):2727-2733.
[23]Decoster L,Wauters I,Vansteenkiste JF.Vaccination therapy for non-small-cell lung cancer:review of agents in phaseⅢdevelopment[J].Ann Oncol,2012,23(6):1387-1393.
[24]Ott PA,Hodi FS,Robert C.CTLA-4 and PD-1/PD-L1 blockade:new immunotherapeutic modalities with durable clinical benefi t in melanoma patients[J].Clin Cancer Res,2013,19(19):5300-5309.
[25]Wolchok JD,Hoos A,O'Day S,et al.Guidelines for the evaluation of immune therapy activity in solid tumors:immune-related response criteria[J].Clin Cancer Res,2009,15(23):7412-7420.
[26]Lynch TJ,Bondarenko I,Luft A,eta l.Ipilimumabin combination with paclitaxel and carboplatin as fi rst-line treatment in stageⅢB/Ⅳnon-small-cell lung cancer:results from a randomized,double-blind,multicenter phaseⅡstudy[J].J Clin Oncol,2012,30(17):2046-2054.
[27]Sundar R,Soong R,Cho BC,et al.Immunotherapy in the treatment of non-small cell lung cancer[J].Lung Cancer,2014,85(2):101-109.
[28]Garon EB,Rizvi N,Patnaik A,et al.Antitumor activity of pembrolizumab(Pembro;MK-3475)and correlation with programmed death ligand 1(PD-L1)expression in a pooled analysis of patients(pts)with advanced non-small cell lung carcinoma(NSCLC)[J].ESMO 2014,Abstract LBA 43.
[29]Langer CJ.Emerging immunotherapies in the treatment of nonsmall cell lung cancer(NSCLC):the role of immune checkpoint inhibitors[J].Am J Clin Oncol,2014.
基本信息:
中图分类号:R734.2
引用信息:
[1]胡毅,陶海涛.晚期非小细胞肺癌的药物治疗进展[J].中国药物应用与监测,2014,11(06):329-333.
基金信息:
军队保健专项课题基金(12BJZ43)